Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (Rituximab)

被引：62

作者：

Kong, HH

Prose, NS

Ware, RE

Hall, RP

机构：

[1] Duke Univ, Med Ctr, Div Dermatol, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Div Pediat Hematol Oncol, Durham, NC 27710 USA

来源：

PEDIATRIC DERMATOLOGY | 2005年 / 22卷 / 05期

关键词：

D O I：

10.1111/j.1525-1470.2005.00118.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Pemphigus vulgaris is an uncommon autoimmune blistering skin disorder that is particularly rare in children. Immunosuppressive treatment can be challenging. Rituximab (anti-CD20 monoclonal antibody) has been used to treat autoimmune disorders by depletion of CD20 B cells. Successful rituximab therapy has been reported in adults with refractory pemphigus vulgaris. We present a girl with childhood pemphigus vulgaris unresponsive to treatment with azathioprine, mycophenolate mofetil, plasmapheresis, and intravenous immunoglobulin with systemic prednisone who responded to treatment with rituximab. She had a corresponding decline in circulating antibodies against desmoglein 1 and 3 and a decline in diphtheria and tetanus-specific antibody titers.

引用

页码：461 / 464

页数：4

共 15 条

[1]

Anolik IH, 2001, ARTHRITIS RHEUM, V44, pS387

[2] Rituximab therapy for multisystem autoimmune diseases in pediatric patients [J].